FDA Approves Merck's Keytruda and Keytruda Qlx for Platinum-Resistant Ovarian Cancer (KEYTR, MRK)

The U.S. Food and Drug Administration approved Merck's KEYTRUDA and KEYTRUDA Qlx for treatment of platinum-resistant ovarian cancer, expanding the company's oncology portfolio. The approvals are based on pivotal trials showing improved progression-free survival and overall survival over placebo. Merck (MRK) shares closed at $54.83 on February 9, 2026, up 1.8% on the NASDAQ. The new indications are expected to broaden KEYTRUDA's use and potentially drive growth in Merck's oncology segment.